{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:05:14Z","timestamp":1792555514038,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.toxicon.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T11:00:02Z","timestamp":1439031602000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"PA","title":["Clinical differences between botulinum neurotoxin type A and B"],"prefix":"10.1016","volume":"107","author":[{"given":"Anna Rita","family":"Bentivoglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Del Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ialongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a04","key":"10.1016\/j.toxicon.2015.08.001_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-1331.2006.01649.x","article-title":"Using translational medicine to understand clinical differences between botulinum toxin formulations","volume":"13","author":"Aoki","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"Suppl.\u00a08","key":"10.1016\/j.toxicon.2015.08.001_bib2","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.toxicon.2009.02.034","article-title":"Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action","volume":"54","author":"Atassi","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2011.04.019","article-title":"Flu-like symptoms following botulinum toxin therapy","volume":"58","author":"Baizabal-Carvallo","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jit449","article-title":"A\u00a0novel strain of Clostridium botulinum that produces type B and type H botulinum toxins","volume":"209","author":"Barash","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.toxicon.2015.08.001_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2005.01095.x","article-title":"The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences","volume":"12","author":"Barnes","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00042728-200503000-00002","article-title":"Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis","volume":"31","author":"Baumann","year":"2005","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.toxicon.2015.08.001_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-4632.2004.02531.x","article-title":"Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis","volume":"44","author":"Baumann","year":"2005","journal-title":"Int. J. Dermatol"},{"key":"10.1016\/j.toxicon.2015.08.001_bib9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A\u00a0new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","article-title":"Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs","volume":"15","author":"Bentivoglio","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2015.08.001_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1468-1331.2008.02507.x","article-title":"Lo Fermo S, Albanese A outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm","volume":"16","author":"Bentivoglio","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10072-011-0672-7","article-title":"Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story","volume":"33","author":"Bentivoglio","year":"2012","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.toxicon.2015.08.001_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","article-title":"Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia","volume":"20","author":"Berman","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.otohns.2005.09.008","article-title":"Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia","volume":"133","author":"Blitzer","year":"2005","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.toxicon.2015.08.001_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","article-title":"Botulinum toxin therapy, immunologic resistance, and problems with available materials","volume":"46","author":"Borodic","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.apmr.2003.08.077","article-title":"Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial","volume":"85","author":"Brashear","year":"2004","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2015.08.001_bib18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1517\/13543784.10.12.2191","article-title":"Botulinum toxin type B: a new injectable treatment for cervical dystonia","volume":"10","author":"Brashear","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.toxicon.2015.08.001_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/BTT.S65603","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.toxicon.2015.08.001_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/JB.4.5.541-553.1919","article-title":"The occurrence of Bacillus botulinus in nature","volume":"4","author":"Burke","year":"1919","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clindermatol.2003.12.027","article-title":"Botulinum toxin type B (Myobloc): pharmacology and biochemistry","volume":"22","author":"Callaway","year":"2004","journal-title":"Clin. Dermatol"},{"key":"10.1016\/j.toxicon.2015.08.001_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/mus.21343","article-title":"Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg","volume":"40","author":"Carli","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.toxicon.2015.08.001_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNF.0b013e318263163c","article-title":"Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials","volume":"35","author":"Chinnapongse","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/jnnp.74.5.687","article-title":"Botulinum toxin type B in blepharospasm and hemifacial spasm","volume":"74","author":"Colosimo","year":"2003","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.08.001_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","article-title":"Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review","volume":"22","author":"Colosimo","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2015.08.001_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","article-title":"Secondary non-responsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test","volume":"21","author":"Cordivari","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib30","first-page":"CD004315","article-title":"Botulinum toxin type B for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2015.08.001_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/brain\/121.4.547","article-title":"Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia","volume":"121","author":"Dauer","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.toxicon.2015.08.001_bib32","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.toxicon.2015.08.001_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1081\/IMM-120016244","article-title":"Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response","volume":"31","author":"Dolimbek","year":"2002","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.toxicon.2015.08.001_bib34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/infdis\/jit450","article-title":"Molecular characterization of a novel botulinum neurotoxin type H gene","volume":"209","author":"Dover","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.toxicon.2015.08.001_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","article-title":"Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis","volume":"49","author":"Dressler","year":"2003","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib36","first-page":"904","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure","volume":"252","author":"Dressler","year":"2005","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000052139","article-title":"Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay","volume":"45","author":"Dressler","year":"2001","journal-title":"Eur. Neurol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.toxicon.2015.08.001_bib38","article-title":"Safety aspects of high-dose Xeomin therapy","volume":"253","author":"Dressler","year":"2006","journal-title":"J.\u00a0Neurol."},{"issue":"Suppl.\u00a08","key":"10.1016\/j.toxicon.2015.08.001_bib39","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a08","key":"10.1016\/j.toxicon.2015.08.001_bib40","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/mds.20010","article-title":"Different types of botulinum toxin in humans","volume":"19","author":"Eleopra","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome","volume":"67","author":"Esquenazi","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.toxicon.2015.08.001_bib43","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","article-title":"Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia","volume":"20","author":"Factor","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archopht.1984.01040031184014","article-title":"Treatment of blepharospasm with botulinum toxin. A preliminary report","volume":"102","author":"Frueh","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410290407","article-title":"Change in pattern of muscle activity following botulinum toxin injections for torticollis","volume":"29","author":"Gelb","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/toxins5040776","article-title":"Continuation of long-term care for cervical dystonia at an academic movement disorders clinic","volume":"5","author":"Gill","year":"2013","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.toxicon.2015.08.001_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: neutralizing and non neutralizing antibodies-therapeutic consequences","volume":"147","author":"Goschel","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib49","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum neurotoxin is shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.toxicon.2015.08.001_bib50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","article-title":"Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies","volume":"66","author":"Hanna","year":"1999","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.08.001_bib53","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","article-title":"Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response","volume":"50","author":"Hanna","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib54","series-title":"Therapy with Botulinum Toxin","first-page":"93","article-title":"Immunogenicity of the neurotoxins of Clostridium botulinum","author":"Hatheway","year":"1994"},{"key":"10.1016\/j.toxicon.2015.08.001_bib55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181692735","article-title":"Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A","volume":"32","author":"Hunt","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib57","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199104253241707","article-title":"Therapeutic uses of botulinum toxin","volume":"324","author":"Jankovic","year":"1991","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.toxicon.2015.08.001_bib58","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","article-title":"Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia","volume":"67","author":"Jankovic","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib59","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib60","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.08.001_bib62","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/infdis\/jiu211","article-title":"Validity of botulinum neurotoxin serotype H","volume":"210","author":"Johnson","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.toxicon.2015.08.001_bib63","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1021\/ac504716v","article-title":"Functional characterization of botulinum neurotoxin serotype H as a hybrid of known Serotypes F and A (BoNT F\/A)","volume":"87","author":"Kalb","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.toxicon.2015.08.001_bib64","first-page":"1","article-title":"Vergiftung durch verdorbene W\u00fcrste","volume":"3","author":"Kerner","year":"1817","journal-title":"T\u00fcbinger Bl\u00e4tter f\u00fcr Naturwissenschaften Arzneykd."},{"key":"10.1016\/j.toxicon.2015.08.001_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870120116","article-title":"The EBD test\u2013a clinical test for the detection of antibodies to botulinum toxin type A","volume":"12","author":"Kessler","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib66","first-page":"265","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2133.2010.10085.x","article-title":"Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study","volume":"164","author":"Kranz","year":"2011","journal-title":"Br. J. Dermatol"},{"key":"10.1016\/j.toxicon.2015.08.001_bib68","first-page":"886","article-title":"Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions","volume":"32","author":"Kranz","year":"2006","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.toxicon.2015.08.001_bib69","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02284114","article-title":"Beitr\u00e4ge zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus","volume":"65","author":"Leuchs","year":"1920","journal-title":"Ztschr Hyg. u Infekt."},{"key":"10.1016\/j.toxicon.2015.08.001_bib72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib73","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/DSS.0000000000000178","article-title":"Botulinum toxin type B: pH change reduces injection pain, retains efficacy","volume":"40","author":"Lowe","year":"2014","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.toxicon.2015.08.001_bib74","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/14764172.2012.738913","article-title":"A\u00a0randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines","volume":"14","author":"Moers-Carpi","year":"2012","journal-title":"J.\u00a0Cosmet. Laser Ther."},{"key":"10.1016\/j.toxicon.2015.08.001_bib75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"Muller","year":"2009","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.08.001_bib76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.08.001_bib77","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"N\u00fcssgens","year":"1997","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.toxicon.2015.08.001_bib80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A\u00a0double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib81","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.50.5.1463","article-title":"A\u00a0radioimmuno-precipitation assay for antibodies to botulinum A","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib82","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Myobloc\/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-na\u00efve patients with cervical dystonia: randomized, double-blind, non-inferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib97","unstructured":"Petracca, M., Guidubaldi, A., Ricciardi, L., Ialongo, T., Del Grande, A., Mulas, D., Di Stasio, E., Bentivoglio, A.R., Botulinum Toxin A and B in sialorrhea: long-term data and literature overview, Toxicon: This issue."},{"key":"10.1016\/j.toxicon.2015.08.001_bib83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/jocd.12001","article-title":"Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines","volume":"11","author":"Prager","year":"2012","journal-title":"J.\u00a0Cosmet. Dermatol"},{"key":"10.1016\/j.toxicon.2015.08.001_bib84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up","volume":"90","author":"Ramirez-Castaneda","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.08.001_bib85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.08.001_bib86","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2013Dysport and Botox\u2013assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2011.07.016","article-title":"Clinical failure of botulinum toxin A in movement disorders","volume":"18","author":"Savica","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib88","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib89","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus","volume":"79","author":"Scott","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.toxicon.2015.08.001_bib90","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","article-title":"Human response to botulinum toxin injection: type B compared with type A","volume":"49","author":"Sloop","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib91","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib92","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/mds.21435","article-title":"Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study","volume":"22","author":"Trosch","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib93","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.870120526","article-title":"BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)","volume":"12","author":"Truong","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.08.001_bib94","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1212\/WNL.45.11.2109","article-title":"Botulinum toxin type B in the treatment of cervical dystonia: a pilot study","volume":"45","author":"Tsui","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.08.001_bib95","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/clinids\/1.4.701","volume":"1","author":"van Ermengem","year":"1979","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.toxicon.2015.08.001_bib96","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","article-title":"Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance","volume":"43","author":"Zuber","year":"1993","journal-title":"Neurology"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115300313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115300313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T03:21:17Z","timestamp":1653016877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010115300313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":97,"alternative-id":["S0041010115300313"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.08.001","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical differences between botulinum neurotoxin type A and B","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}